Latest Market Entry News

Talga Group has begun trading on the U.S. OTCQX market, enhancing liquidity and visibility among American investors without issuing new shares. This move complements its existing listings on the ASX and Börse Frankfurt, positioning Talga for growth amid rising demand for sustainable battery materials.

SRJ Technologies has inked a US$6 million joint venture in the Middle East and launched a fully underwritten A$2.5 million entitlement offer to accelerate its regional expansion.

Ovanti Limited has appointed Peter Maher, a seasoned BNPL executive from Zip Co, to lead its US expansion, while exploring a NASDAQ listing via dual-listing or SPAC merger and reconsidering the sale of a key dividend-yielding asset.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

SportsHero Limited has advanced its iGV Family Game Pass commercialization with launches in Indonesia and the Philippines, backed by new Telco partnerships and a A$1.65 million capital raise.

Provaris Energy has marked significant milestones in Q2 2025 with a key MOU with global shipping leader 'K' LINE and a joint venture formation with Yinson to commercialise proprietary hydrogen and carbon dioxide transport technologies.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Prescient Therapeutics has raised nearly $10 million through a placement and share purchase plan to advance its promising PTX-100 targeted cancer therapy into pivotal clinical stages.

Felix Group Holdings Ltd reported a strong FY25 with record contract expansions and new customer acquisitions, boosting enterprise ARR by 20% and achieving positive operating cash flow for the first time. The company is now focused on monetising its growing Vendor Marketplace and expanding internationally.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.

PainChek Limited has secured a A$7.5 million placement to fuel its international expansion, with US FDA clearance for its adult pain assessment app expected imminently. The company reports strong license growth and a 26% revenue increase year-on-year.